# Efficacy, Safety and Pharmacokinetics of Sugammadex (Org 25969; MK-8616) at 3 Different Time Points After 0.6 mg/kg Esmeron® in Male Participants (P05940; MK-8616-020).

> **NCT03519854** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 99 (actual)

## Conditions studied

- Neuromuscular Blockade

## Interventions

- **DRUG:** Placebo
- **DRUG:** Sugammadex
- **DRUG:** Esmeron®

## Key facts

- **NCT ID:** NCT03519854
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-12-01
- **Primary completion:** 2003-06-01
- **Final completion:** 2003-06-01
- **Target enrollment:** 99 (ACTUAL)
- **Last updated:** 2019-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03519854

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03519854, "Efficacy, Safety and Pharmacokinetics of Sugammadex (Org 25969; MK-8616) at 3 Different Time Points After 0.6 mg/kg Esmeron® in Male Participants (P05940; MK-8616-020).". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03519854. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*